<DOC>
	<DOCNO>NCT00213486</DOCNO>
	<brief_summary>The standard non surgical therapy locally advanced esophageal cancer base definitive concurrent chemoradiotherapy regimen fluorouracil cisplatin . One alternative regimen study combination weekly cisplatin irinotecan schedule radiotherapy . This multicentric phase II clinical trial primarily aim evaluate clinical complete response rate secondary objective toxicity profile survival .</brief_summary>
	<brief_title>Weekly Cisplatin/Irinotecan Radiotherapy Patients With Locally Advanced Esophageal Cancer : Phase II Trial</brief_title>
	<detailed_description>Chemotherapy weekly cisplatin 30 mg/m2 AND Irinotecan 60 mg/m2 administer days1,8,22,29 concurrently radiotherapy day 43,50,64,71 . Radiotherapy deliver day 43 75 50Gy 25 fractions/5 week .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>esophageal carcinoma ( squamous cell adenocarcinoma ) histologically confirm performance status &lt; OR=2 ( ECOG ) caloric intake &gt; 1500 KCal/d serum albumin &gt; 32 gr/l serum creatinine &lt; 120 microgr/l total serum bilirubin &lt; 1.5 mg/ml prior chemotherapy radiotherapy surgery esophageal neoplasm prior history malignancy cell carcinoma skin , siyu cervical carcinoma , head neck carcinoma complete response since 3 year write informed consent Gilbert 's syndrome cardiac disease NYHA class 3 4 myocardial infarction within previous 6 month metastatic disease histologically prove invasion tracheobronchial tree metastatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>